Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT with Low-Dose IL-2 for Refractory Crohn's Disease
NCT02676622Phase 2Withdrawn
- Sponsor
- Nationwide Children's Hospital
- Start
- Apr 2013
- Primary completion
- Apr 2013
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in Crohn's disease, sponsored by Nationwide Children's Hospital. Primary endpoints: Transplant Related Mortality at 100 days and Incidence of Severe Toxicity at 100 days. Planned start Apr 2013; status: withdrawn.
02
Drugs
aldesleukin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02676622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676622.